Published in J Gastroenterol Hepatol on May 01, 2012
Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol (2014) 1.04
Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives. World J Gastroenterol (2014) 1.00
Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol (2015) 0.97
Dihydromyricetin induces apoptosis and inhibits proliferation in hepatocellular carcinoma cells. Oncol Lett (2014) 0.91
Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy. Cell Mol Gastroenterol Hepatol (2015) 0.86
Interaction of the hepatitis B spliced protein with cathepsin B promotes hepatoma cell migration and invasion. J Virol (2012) 0.83
Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol (2013) 0.83
Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. World J Gastroenterol (2016) 0.83
TGF-β Mediated Crosstalk Between Malignant Hepatocyte and Tumor Microenvironment in Hepatocellular Carcinoma. Cancer Growth Metastasis (2014) 0.81
Role of the tissue microenvironment as a therapeutic target in hepatocellular carcinoma. World J Gastroenterol (2014) 0.81
Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights. World J Gastroenterol (2014) 0.78
Reciprocal activating crosstalk between c-Met and caveolin 1 promotes invasive phenotype in hepatocellular carcinoma. PLoS One (2014) 0.78
Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways. PLoS One (2015) 0.78
Drug development for hepatocellular carcinoma: knowing the past helps to understand the future. Oncologist (2014) 0.76
Targeting late SV40 factor: is the achilles heel of hepatocarcinogenesis revealed? World J Gastroenterol (2012) 0.76
Proteomics approaches for early detection and targeted therapy of hepatocellular carcinoma. World J Gastrointest Oncol (2017) 0.75
Hepatocellular Carcinoma Patients With Performance Status 1 Deserve New Classification and Treatment Algorithm in the BCLC System. Medicine (Baltimore) (2015) 0.75
Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma. World J Gastroenterol (2015) 0.75
Recombinant adeno-associated virus expressing a p53-derived apoptotic peptide (37AA) inhibits HCC cells growth in vitro and in vivo. Oncotarget (2017) 0.75
Antiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract. BMC Complement Altern Med (2016) 0.75
Huaier polysaccharide induces apoptosis in hepatocellular carcinoma cells through p38 MAPK. Oncol Lett (2016) 0.75
Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. Chin J Cancer (2014) 0.75
Magnetic alginate microspheres detected by MRI fabricated using microfluidic technique and release behavior of encapsulated dual drugs. Int J Nanomedicine (2017) 0.75
Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Diseases (2015) 0.75
New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol (2008) 2.65
High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol (2008) 2.56
Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst (2005) 2.30
Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. Clin Cancer Res (2002) 1.57
Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol (2010) 1.55
Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. J Gastroenterol Hepatol (2011) 1.22
Predictors of lymphedema in patients with breast cancer undergoing axillary lymph node dissection in Hong Kong. Nurs Res (2008) 1.22
Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol (2011) 1.21
TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer (2009) 1.13
Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas. Clin Cancer Res (2003) 1.09
Re: roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. J Natl Cancer Inst (2013) 1.06
Chemotherapy induced complete remission in malignant phyllodes tumor of the prostate metastasizing to the lung. J Urol (2002) 1.06
The epigenetic modifier PRDM5 functions as a tumor suppressor through modulating WNT/β-catenin signaling and is frequently silenced in multiple tumors. PLoS One (2011) 1.05
A sensitive and specific liquid chromatography-tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patients. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 1.05
Supportive care needs in Hong Kong Chinese women confronting advanced breast cancer. Psychooncology (2012) 1.03
Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. Cancer Genet Cytogenet (2004) 1.03
Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer -- a retrospective review of Chinese patients and comparison with an historic Western series. Radiother Oncol (2002) 1.02
Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. Chin J Cancer (2011) 1.01
Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial. Obstet Gynecol (2013) 1.00
Knowledge, perceptions, and attitudes of Hong Kong Chinese women on screening mammography and early breast cancer management. Breast J (2005) 0.95
Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion. Liver Int (2010) 0.95
The tumor suppressor gene DLEC1 is frequently silenced by DNA methylation in hepatocellular carcinoma and induces G1 arrest in cell cycle. J Hepatol (2007) 0.94
Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. Support Care Cancer (2010) 0.93
An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal alpha-fetoprotein levels or abdominal ultrasonography results. J Clin Oncol (2005) 0.92
Embolization efficacy and treatment effectiveness of transarterial therapy for unresectable hepatocellular carcinoma: a case-controlled comparison of transarterial ethanol ablation with lipiodol-ethanol mixture versus transcatheter arterial chemoembolization. J Vasc Interv Radiol (2009) 0.92
Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma. Int J Oncol (2011) 0.91
Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study. J Epidemiol Community Health (2010) 0.90
Role of alpha-fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both? Future Oncol (2009) 0.90
The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. Invest New Drugs (2009) 0.88
Frequent detection of the replicative form of TT virus DNA in peripheral blood mononuclear cells and bone marrow cells in cancer patients. J Med Virol (2002) 0.88
Quality of life of palliative care patients in the last two weeks of life. J Pain Symptom Manage (2002) 0.87
International validation of the Chinese university prognostic index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. Chin J Cancer (2014) 0.87
Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma. Biochem Pharmacol (2012) 0.87
Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One (2013) 0.86
Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients. J Cancer Res Clin Oncol (2012) 0.85
Performance of serum α-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. HPB (Oxford) (2013) 0.85
A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. Cancer (2011) 0.84
Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization. Radiology (2013) 0.83
The evolution of supportive care needs trajectories in women with advanced breast cancer during the 12 months following diagnosis. Support Care Cancer (2013) 0.82
Brain metastasis responding to gefitinib alone. Oncology (2004) 0.82
Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma. Int J Hepatol (2013) 0.81
Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma. Liver Int (2011) 0.81
Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. Cancer Chemother Pharmacol (2013) 0.80
T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer. J Med Virol (2011) 0.79
Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study. Oncology (2007) 0.79
Unusual abdominal tumors: case 4. Multiple lymphomatous polyposis in mantle cell lymphoma. J Clin Oncol (2003) 0.79
T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer. Clin Vaccine Immunol (2010) 0.79
Transarterial ethanol ablation of hepatocellular carcinoma with lipiodol ethanol mixture: phase II study. J Vasc Interv Radiol (2008) 0.78
Selecting the right patients for testing novel agents in hepatocellular carcinoma: who, when and how? Asia Pac J Clin Oncol (2013) 0.78
Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer. Oncology (2005) 0.77
A comparison of three transarterial lipiodol-based formulations for hepatocellular carcinoma: in vivo biodistribution study in humans. Cardiovasc Intervent Radiol (2007) 0.77
A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer. Acta Oncol (2004) 0.77
False-negative rate of abdominal sonography for detecting hepatocellular carcinoma in patients with hepatitis B and elevated serum alpha-fetoprotein levels. AJR Am J Roentgenol (2004) 0.76
Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer. J Thorac Oncol (2007) 0.76
Delayed radiation myelopathy after concurrent chemoradiation for hypopharyngeal-esophageal carcinoma. Acta Oncol (2005) 0.75
A simple and sensitive high-performance liquid chromatographic method for quantification of PXD101, a histone deacetylase inhibitor in human plasma. Ther Drug Monit (2007) 0.75
Novel therapeutic targets and predictive markers for hepatocellular carcinoma. Expert Opin Ther Targets (2015) 0.75